P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation
Paul G. Richardson,Angela R. Smith,Brandon M. Triplett,Nancy A. Kernan,Stephan A. Grupp,Joseph H. Antin,Leslie Lehmann,Maja Miloslavsky,Robin Hume,Alison L. Hannah,Bijan Nejadnik,Robert J. Soiffer +11 more
TL;DR: The relationship between Day +100 survival and treatment initiation before/after specific days post‐diagnosis showed superior survival when treatment was initiated closer to VOD/SOS diagnosis with a statistically significant trend over time for better outcomes with earlier treatment initiation.
Journal ArticleDOI
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Paul G. Richardson,Sara Bringhen,Peter M. Voorhees,Torben Plesner,Ulf-Henrik Mellqvist,Brandi Reeves,Claudia E. Paba-Prada,Hanan Zubair,Catriona Byrne,Dharminder Chauhan,Kenneth C. Anderson,Eva Nordström,Johan Harmenberg,Antonio Palumbo,Pieter Sonneveld +14 more
TL;DR: A phase 1-2 study of melflufen and dexamethasone in patients with relapsed and refractory multiple myeloma to determine the maximum tolerated dose and to investigate its safety and efficacy is completed.
Journal ArticleDOI
Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease
Luba Benimetskaya,Sijian Wu,Anatoliy M. Voskresenskiy,Cinara Echart,Jin-Feng Zhou,Joongho Shin,Massimo Iacobelli,Paul G. Richardson,Kanyalakshmi Ayyanar,Cy A. Stein +9 more
TL;DR: The data suggest that DF may provide a stimulus to the sinusoidal endothelium of a liver that has suffered a severe angiotoxic event, thus helping to ameliorate the clinical sVOD/MOF syndrome.
Journal ArticleDOI
Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
Rao Prabhala,Rao Prabhala,Rao Prabhala,Mariateresa Fulciniti,Mariateresa Fulciniti,Dheeraj Pelluru,Naim U. Rashid,A Nigroiu,Puru Nanjappa,Christine Pai,Saem Lee,Nithya Prabhala,R. L. Bandi,Richard S. Smith,Suzan Lazo-Kallanian,S Valet,Noopur Raje,Jason S. Gold,Jason S. Gold,Paul G. Richardson,John F. Daley,Kenneth C. Anderson,Kenneth C. Anderson,Seth Ettenberg,F Di Padova,Nikhil C. Munshi,Nikhil C. Munshi,Nikhil C. Munshi +27 more
TL;DR: Pre-clinical observations suggest efficacy of AIN457 in myeloma and provide the rationale for its clinical evaluation for anti-myeloma effects and for improvement of bone disease.
Journal ArticleDOI
Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
Malin Wickström,Peter Nygren,Rolf Larsson,Johan Harmenberg,Jakob Lindberg,Per Sjöberg,Markus Jerling,Fredrik Lehmann,Paul G. Richardson,Kenneth C. Anderson,Dharminder Chauhan,Joachim Gullbo +11 more
TL;DR: It is hypothesized that melflufen could provide better efficacy but no more toxicity than what is achieved with melphalan, an assumption so far supported by experiences from hollow fiber and xenograft studies in rodents as well as by clinical data from patients with solid tumors and multiple myeloma.